982 related articles for article (PubMed ID: 24534255)
21. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis.
Zhou J; Febbraio M; Wada T; Zhai Y; Kuruba R; He J; Lee JH; Khadem S; Ren S; Li S; Silverstein RL; Xie W
Gastroenterology; 2008 Feb; 134(2):556-67. PubMed ID: 18242221
[TBL] [Abstract][Full Text] [Related]
22. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.
Rogue A; Renaud MP; Claude N; Guillouzo A; Spire C
Toxicol Appl Pharmacol; 2011 Jul; 254(1):18-31. PubMed ID: 21515302
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.
Yan F; Wang Q; Xu C; Cao M; Zhou X; Wang T; Yu C; Jing F; Chen W; Gao L; Zhao J
PLoS One; 2014; 9(6):e99245. PubMed ID: 24926685
[TBL] [Abstract][Full Text] [Related]
24. A PPAR Pan Agonist, MHY2013 Alleviates Age-Related Hepatic Lipid Accumulation by Promoting Fatty Acid Oxidation and Suppressing Inflammation.
An HJ; Lee B; Kim SM; Kim DH; Chung KW; Ha SG; Park KC; Park YJ; Kim SJ; Yun HY; Chun P; Yu BP; Moon HR; Chung HY
Biol Pharm Bull; 2018; 41(1):29-35. PubMed ID: 29311481
[TBL] [Abstract][Full Text] [Related]
25. CYP4F3B expression is associated with differentiation of HepaRG human hepatocytes and unaffected by fatty acid overload.
Madec S; Cerec V; Plée-Gautier E; Antoun J; Glaise D; Salaun JP; Guguen-Guillouzo C; Corlu A
Drug Metab Dispos; 2011 Oct; 39(10):1987-96. PubMed ID: 21778351
[TBL] [Abstract][Full Text] [Related]
26. Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4.
Sanguino E; Roglans N; Alegret M; Sánchez RM; Vázquez-Carrera M; Laguna JC
Br J Pharmacol; 2005 Aug; 145(7):853-61. PubMed ID: 15912134
[TBL] [Abstract][Full Text] [Related]
27. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Sahebkar A; Chew GT; Watts GF
Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
[TBL] [Abstract][Full Text] [Related]
28. Co-option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA-induced hepatic steatosis.
Cai D; Li Y; Zhang K; Zhou B; Guo F; Holm L; Liu HY
J Cell Physiol; 2021 Jun; 236(6):4387-4402. PubMed ID: 33184849
[TBL] [Abstract][Full Text] [Related]
29. Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging.
Kim SM; Lee B; An HJ; Kim DH; Park KC; Noh SG; Chung KW; Lee EK; Kim KM; Kim DH; Kim SJ; Chun P; Lee HJ; Moon HR; Chung HY
Oncotarget; 2017 Jul; 8(28):46273-46285. PubMed ID: 28545035
[TBL] [Abstract][Full Text] [Related]
30. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC
J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330
[TBL] [Abstract][Full Text] [Related]
31. Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1.
Ziamajidi N; Khaghani S; Hassanzadeh G; Vardasbi S; Ahmadian S; Nowrouzi A; Ghaffari SM; Abdirad A
Food Chem Toxicol; 2013 Aug; 58():198-209. PubMed ID: 23603006
[TBL] [Abstract][Full Text] [Related]
32. Effects of the peroxisome proliferator-activated receptor-alpha agonists clofibrate and fish oil on hepatic fatty acid metabolism in weaned dairy calves.
Litherland NB; Bionaz M; Wallace RL; Loor JJ; Drackley JK
J Dairy Sci; 2010 Jun; 93(6):2404-18. PubMed ID: 20494149
[TBL] [Abstract][Full Text] [Related]
33. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
[TBL] [Abstract][Full Text] [Related]
34. Nuclear receptors and nonalcoholic fatty liver disease.
Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
[TBL] [Abstract][Full Text] [Related]
35. Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding.
Kay HY; Kim WD; Hwang SJ; Choi HS; Gilroy RK; Wan YJ; Kim SG
Antioxid Redox Signal; 2011 Oct; 15(8):2135-46. PubMed ID: 21504366
[TBL] [Abstract][Full Text] [Related]
36. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
Liu J; Tang T; Wang GD; Liu B
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
[No Abstract] [Full Text] [Related]
37. Swertiamarin ameliorates oleic acid induced lipid accumulation and oxidative stress by attenuating gluconeogenesis and lipogenesis in hepatic steatosis.
Patel TP; Rawal K; Soni S; Gupta S
Biomed Pharmacother; 2016 Oct; 83():785-791. PubMed ID: 27490779
[TBL] [Abstract][Full Text] [Related]
38. Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD.
Zheng L; Lv GC; Sheng J; Yang YD
J Gastroenterol Hepatol; 2010 Jan; 25(1):156-63. PubMed ID: 19780876
[TBL] [Abstract][Full Text] [Related]
39. Astaxanthin reduces hepatic lipid accumulations in high-fat-fed C57BL/6J mice via activation of peroxisome proliferator-activated receptor (PPAR) alpha and inhibition of PPAR gamma and Akt.
Jia Y; Wu C; Kim J; Kim B; Lee SJ
J Nutr Biochem; 2016 Feb; 28():9-18. PubMed ID: 26878778
[TBL] [Abstract][Full Text] [Related]
40. Perfluoroalkyl acids-induced liver steatosis: Effects on genes controlling lipid homeostasis.
Das KP; Wood CR; Lin MT; Starkov AA; Lau C; Wallace KB; Corton JC; Abbott BD
Toxicology; 2017 Mar; 378():37-52. PubMed ID: 28049043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
